ZyVersa Therapeutics, Inc.

OTCPK:ZVSA Stock Report

Market Cap: US$1.3m

ZyVersa Therapeutics Management

Management criteria checks 3/4

ZyVersa Therapeutics' CEO is Steve/Steven Glover, appointed in Dec 2022, has a tenure of 3.5 years. total yearly compensation is $622.91K, comprised of 88.3% salary and 11.7% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth $215.87. The average tenure of the management team and the board of directors is 3.5 years and 3.5 years respectively.

Key information

Steve/Steven Glover

Chief executive officer

US$622.9k

Total compensation

CEO salary percentage88.30%
CEO tenure3.5yrs
CEO ownership0.02%
Management average tenure3.5yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve/Steven Glover's remuneration changed compared to ZyVersa Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$24m

Dec 31 2025US$623kUS$550k

-US$25m

Sep 30 2025n/an/a

-US$26m

Jun 30 2025n/an/a

-US$8m

Mar 31 2025n/an/a

-US$9m

Dec 31 2024US$550kUS$550k

-US$9m

Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$106m

Dec 31 2023US$993kUS$550k

-US$106m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$451k

-US$14m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$2mUS$451k

-US$8m

Dec 31 2020US$451kUS$451k

-US$13m

Compensation vs Market: Steve/Steven's total compensation ($USD622.91K) is about average for companies of similar size in the US market ($USD637.50K).

Compensation vs Earnings: Steve/Steven's compensation has increased whilst the company is unprofitable.

CEO

Steve/Steven Glover (66 yo)

3.5yrs
Tenure
US$622,910
Compensation

Mr. Stephen C. Glover, also known as Steve & Steven, is an Independent Director of Oncolytics Biotech Inc. from June 1, 2026. He is Member of Advisory Board of PreveCeutical Medical Inc. from May 24, 2025....

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Glover
Co-Founder3.5yrsUS$622.91k0.016%
$ 215.9
Peter Wolfe
CFO & Secretary3.5yrsUS$427.01k0.0016%
$ 21.0
Karen Cashmere
Chief Commercial Officer3.5yrsUS$486.69k0%
$ 0
3.5yrs
Average Tenure
66yo
Average Age

Experienced Management: ZVSA's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Glover
Co-Founder3.5yrsUS$622.91k0.016%
$ 215.9
Gregory Freitag
Independent Director3.4yrsUS$68.39k0%
$ 0
James Sapirstein
Independent Director3.4yrsUS$69.39k0%
$ 0
Marlene Haffner
Member of Scientific Advisory Boardno datano datano data
Alessia Fornoni
Member of Scientific Advisory Boardno datano datano data
Helen Bramlett
Member of Scientific Advisory Boardno datano datano data
Juan de Rivero Vaccari
Member of Scientific Advisory Boardno datano datano data
Robert Keane
Member of Scientific Advisory Boardno datano datano data
Sharon Adler
Member of Scientific Advisory Boardno datano datano data
W. Dietrich
Member of Scientific Advisory Boardno datano datano data
Min-Chul Park
Independent Director3.5yrsUS$57.39k0%
$ 0
Fernando Fervenza
Member of Renal Scientific Advisory Boardno datano datano data
3.5yrs
Average Tenure
65.5yo
Average Age

Experienced Board: ZVSA's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/23 12:21
End of Day Share Price 2026/06/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ZyVersa Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.